Khan Nazeer Hussain, Mir Maria, Ngowi Ebenezeri Erasto, Zafar Ujala, Khakwani Muhammad Mahtab Aslam Khan, Khattak Saadullah, Zhai Yuan-Kun, Jiang En-She, Zheng Meng, Duan Shao-Feng, Wei Jian-She, Wu Dong-Dong, Ji Xin-Ying
Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Front Bioeng Biotechnol. 2021 Apr 9;9:630055. doi: 10.3389/fbioe.2021.630055. eCollection 2021.
Alzheimer's disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood-brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.
阿尔茨海默病(AD)是一种影响老年人群的毁灭性疾病,其特征是由于海马体中细胞外斑块的形成导致大脑进行性缓慢衰退。AD细胞包括被斑块包围的聚集微管结合蛋白扭曲链缠结。为了在大脑中递送相应药物来应对这些临床病理状况,我们面临着循环血液与脑细胞之间天然形成的强大保护屏障,即血脑屏障(BBB)。纳米药物提供了先进的替代方法,以克服药物跨血脑屏障运输中的挑战。本综述介绍了纳米药物在AD诊断和治疗中的作用进展。我们旨在概述纳米技术如何彻底改变了AD的管理方法,并突出该领域当前的关键瓶颈和未来前景。此外,用于管理AD等脑部疾病的新兴纳米药物可促进相关研究的蓬勃发展及其临床应用。